LitAlert ~~ GeneLit.com

    • Integrated Microfluidic System for Cell-Free DNA Extraction from Plasma for Mutant Gene Detection and Quantification.
    • Cheng YH, Wang CH, Hsu KF, Lee GB.
    • Anal Chem. 2022 Mar 2. doi: 10.1021/acs.analchem.1c04988. Epub ahead of print.
    • Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    • Lorusso D, Guy H, Samyshkin Y, Hawkes C, Estenson K, Coleman RL.
    • Cancers (Basel). 2022 Mar 2;14(5):1285. doi: 10.3390/cancers14051285.
    • Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.
    • Bruno L, Ostinelli A, Waisberg F, Enrico D, Ponce C, Rivero S, Blanco A, Zarba M, Loza M, Fabiano V, Amat M, Pombo MT, Noro L, Chacón M, Coló F, Chacón R, Nadal J, Nervo A, Costanzo V.
    • JCO Precis Oncol. 2022 Mar;6:e2100140. doi: 10.1200/PO.21.00140.
    • A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.
    • Jagannathan G, White MJ, Xian RR, Emens LA, Cimino-Mathews A.
    • Surg Pathol Clin. 2022 Mar;15(1):105-120. doi: 10.1016/j.path.2021.11.007. Epub 2022 Jan 31.
    • Review
    • PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components.
    • O'Sullivan Coyne G, Karlovich C, Wilsker D, Voth AR, Parchment RE, Chen AP, Doroshow JH.
    • Onco Targets Ther. 2022 Feb 24;15:165-180. doi: 10.2147/OTT.S278092.